Search research articles
Contact Us
Filters
Showing results (91-100 of 98) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 98 results.
Assay and Drug Development Technologies
|
May 5, 2007
An automated high throughput liquid chromatography-mass spectrometry process to assess the metabolic stability of drug candidates
Dieter M Drexler, James V Belcastro, Kenneth E Dickinson, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 19, 2016
The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers
Holly D Soares, Maciej Gasior, Jeremy H Toyn, et al.
Journal of Medicinal Chemistry
|
March 2, 2026
Optimization of Covalent Warhead Trajectory for KRAS<sup>G12C</sup> Active-State Inhibition
Matthew L Condakes, Rita L Civiello, Sirish Kaushik Lakkaraju, et al.
Journal of Medicinal Chemistry
|
March 2, 2026
Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS<sup>G12C</sup> Active-State Inhibition
Matthew L Condakes, Rita L Civiello, Brian L Venables, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 19, 2016
Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects
Jeremy H Toyn, Kenneth M Boy, Joseph Raybon, et al.
The Journal of Biological Chemistry
|
June 25, 2008
The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression
Catherine R Burton, Jere E Meredith, Donna M Barten, et al.
International Journal of Alzheimer'S Disease
|
August 7, 2014
Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780
Jeremy H Toyn, Lorin A Thompson, Kimberley A Lentz, et al.
Nature Communications
|
January 31, 2026
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
Matthew L Condakes, Zhuo Zhang, Derek B Danahy, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 98) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 98 results.
Assay and Drug Development Technologies
|
May 5, 2007
An automated high throughput liquid chromatography-mass spectrometry process to assess the metabolic stability of drug candidates
Dieter M Drexler, James V Belcastro, Kenneth E Dickinson, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 19, 2016
The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers
Holly D Soares, Maciej Gasior, Jeremy H Toyn, et al.
Journal of Medicinal Chemistry
|
March 2, 2026
Optimization of Covalent Warhead Trajectory for KRAS<sup>G12C</sup> Active-State Inhibition
Matthew L Condakes, Rita L Civiello, Sirish Kaushik Lakkaraju, et al.
Journal of Medicinal Chemistry
|
March 2, 2026
Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS<sup>G12C</sup> Active-State Inhibition
Matthew L Condakes, Rita L Civiello, Brian L Venables, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 19, 2016
Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects
Jeremy H Toyn, Kenneth M Boy, Joseph Raybon, et al.
The Journal of Biological Chemistry
|
June 25, 2008
The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression
Catherine R Burton, Jere E Meredith, Donna M Barten, et al.
International Journal of Alzheimer'S Disease
|
August 7, 2014
Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780
Jeremy H Toyn, Lorin A Thompson, Kimberley A Lentz, et al.
Nature Communications
|
January 31, 2026
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
Matthew L Condakes, Zhuo Zhang, Derek B Danahy, et al.
Page
of 10